Overview

A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity

Status:
COMPLETED

Trial end date:
2025-09-29

Target enrollment:

Participant gender:

Summary

The aim of this study is to evaluate the safety and tolerability, and pharmacodynamics (PD) of AZD4144 administered as repeated daily oral dosing.

Phase:

PHASE1

Details

Lead Sponsor:

AstraZeneca